AzTrials
AzTrials

Condition

ADHD Clinical Trials

Studies of adhd, matched by condition name and medical subject headings. Start with those open to enrolment.

758 registered studies

In numbers

Open to volunteers
164
Active
186
With results posted
133
All registered
758

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 164
  • Attention Deficit Hyperactivity Disorder (ADHD)

    A Long-term Trial of EB-1020 in Adult Patients With ADHD

    • Recruiting
    • Age: 18 to 55 years
    • Phase 3
    • Pill or oral medicine

    The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan

    Trial name
    NCT06926829
    Testing
    EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
    Where
    Japan
    Volunteers
    180 people
    Sponsor
    Otsuka Pharmaceutical Co., Ltd.
    Can I take part? NCT06926829
  • Attention Deficit Hyperactivity Disorder (ADHD)

    Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

    • Recruiting
    • Age: 18 to 55 years
    • Phase 2/3
    • Pill or oral medicine

    The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

    Trial name
    NCT06931080
    Testing
    EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
    Where
    Japan
    Volunteers
    630 people
    Sponsor
    Otsuka Pharmaceutical Co., Ltd.
    Can I take part? NCT06931080
  • ADHD, Autism Spectrum Disorder

    AWARE: Management of ADHD in Autism Spectrum Disorder

    • Recruiting
    • Age: 4 to 17 years
    • Phase 4
    • Pill or oral medicine

    This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism.

    Trial name
    NCT05916339
    Testing
    Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
    Where
    13 sites in United States, Canada
    Volunteers
    500 people
    Sponsor
    Daniel Coury
    Can I take part? NCT05916339
  • Attention Deficit Disorder With Hyperactivity (ADHD), Autism Spectrum Disorder (ASD)

    External Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated Symptoms

    • Recruiting
    • Age: 7 to 14 years
    • Medical device

    The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD).

    Trial name
    eTNS CARES (NCT07214545)
    Testing
    Trigeminal Nerve Stimulation
    Where
    United States
    Volunteers
    60 people
    Sponsor
    University of California, San Francisco
    Can I take part? eTNS CARES
  • Attention-Deficit/Hyperactivity Disorder (ADHD)

    Developing Virtual Reality Programs to Address Social Skills Deficits in Youth With ADHD

    • Not yet recruiting
    • Age: 10 to 15 years
    • Medical device

    Researchers at OpenMindXR, in collaboration with Indiana University, are conducting a paid research study evaluating an innovative virtual reality (VR)-based intervention designed to support social and emotional skill development…

    Trial name
    NCT07882823
    Testing
    VIP Suite
    Volunteers
    48 people
    Sponsor
    Indiana University
    Can I take part? NCT07882823
  • ADHD

    Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Recruiting
    • Age: 6 to 11 years
    • Phase 3
    • Pill or oral medicine

    This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to <12 years with ADHD.

    Trial name
    NCT07717879
    Testing
    Solriamfetol Dose A, Solriamfetol Dose B
    Where
    30 sites in United States
    Volunteers
    468 people
    Sponsor
    Axsome Therapeutics, Inc.
    Can I take part? NCT07717879
  • ADHD

    Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Recruiting
    • Age: 12 to 17 years
    • Phase 3
    • Pill or oral medicine

    This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to <18 years with ADHD.

    Trial name
    NCT07717892
    Testing
    Solriamfetol Dose A, Solriamfetol Dose B
    Where
    28 sites in United States
    Volunteers
    468 people
    Sponsor
    Axsome Therapeutics, Inc.
    Can I take part? NCT07717892
  • ADHD

    An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD

    • Enrolling by invitation
    • Age: 6 to 18 years
    • Phase 3
    • Pill or oral medicine

    This study is a Phase 3, multi-center, open-label trial to evaluate the long-term safety of solriamfetol in children and adolescents with ADHD.

    Trial name
    NCT07773883
    Testing
    Solriamfetol
    Where
    7 sites in United States
    Volunteers
    300 people
    Sponsor
    Axsome Therapeutics, Inc.
    Can I take part? NCT07773883
  • ADHD

    Virtual Reality Attention Management

    • Recruiting
    • Age: 8 to 12 years
    • Medical device

    Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects.

    Trial name
    VRAM (NCT03221244)
    Testing
    VR Treatment, VR Active Control
    Where
    United States
    Volunteers
    50 people
    Sponsor
    University of California, Davis
    Can I take part? VRAM
  • Autism Disorder, Language Development Disorders

    Rural Autistic Individuals - Supporting Expression

    • Recruiting
    • Age: 2 years and older
    • Lifestyle or therapy programme

    This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are…

    Conditions
    Autism Disorder, Language Development Disorders, ADHD, Typical Development
    Trial name
    RAISE (NCT07054866)
    Testing
    Speech-Gesture combinations
    Where
    United States
    Volunteers
    50 people, healthy volunteers welcome
    Sponsor
    Montana State University
    Can I take part? RAISE

Completed, with results posted

All –
  • ADHD, Parenting

    Treating Parents With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial

    • Completed
    • Age: 3 to 65 years
    • Phase 3
    • Lifestyle or therapy programme
    • Results posted

    This study will compare the effectiveness of combined parental stimulant medication and behavioral parent training (BPT) versus BPT alone on child ADHD-related impairment (primary outcome), child ADHD and externalizing symptoms…

    Trial name
    TPAC (NCT04240756)
    Testing
    Behavioral Parent Training, Extended release mixed amphetamine salts (MAS)
    Where
    United States
    Volunteers
    269 people
    Sponsor
    University of Maryland, College Park
    Can I take part? TPAC
  • ADHD, ADHD - Combined Type

    Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

    • Completed
    • Age: 18 to 55 years
    • Phase 3
    • Pill or oral medicine
    • Results posted

    The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.

    Conditions
    ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
    Trial name
    NCT05631626
    Testing
    CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg
    Where
    United States
    Volunteers
    26 people
    Sponsor
    Cingulate Therapeutics
  • ADHD

    Improving the Outcomes of Adolescents With ADHD Via a Pre-visit Question Prompt List/Video Intervention

    • Completed
    • Age: 11 to 17 years
    • Lifestyle or therapy programme
    • Results posted

    The investigators propose to conduct a pilot randomized controlled feasibility trial to evaluate the feasibility and effectiveness of a pre-visit intervention to improve communication about attention deficit hyperactivity…

    Trial name
    NCT05835362
    Testing
    Question Prompt List, Video Only
    Where
    United States
    Volunteers
    252 people
    Sponsor
    University of North Carolina, Chapel Hill
  • Adult ADHD

    Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

    • Completed
    • Age: 18 to 55 years
    • Phase 2
    • Pill or oral medicine
    • Injection or infusion
    • Results posted

    This was a Phase 2 exploratory study to evaluate the efficacy and safety of EB-1020 SR (centanafadine sustained release [CTN SR]) in treating participants who met Diagnostic and Statistical Manual of Mental Disorders, Fourth…

    Trial name
    NCT01939353
    Testing
    CTN SR
    Where
    3 sites in United States
    Volunteers
    45 people
    Sponsor
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Can I take part? NCT01939353
  • Attention-Deficit Hyperactivity Disorder (ADHD)

    PDC-1421 Treatment in Adult Patients With ADHD

    • Completed
    • Age: 18 to 70 years
    • Phase 2
    • Pill or oral medicine
    • Results posted

    Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.

    Trial name
    NCT05202327
    Testing
    PDC-1421 Capsule
    Where
    6 sites in United States, Taiwan
    Volunteers
    99 people
    Sponsor
    BioLite, Inc.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in